Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAD-1883 in Adults With Spinocerebellar Ataxia
NCT04301284Phase 2
Key facts
- Status
- Withdrawn
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Countries
- 1
- Sponsor
- Cadent Therapeutics
- Modality
- Small Molecules
- Drugs
- rimtuzalcap
- Conditions
- spinocerebellar ataxia (SCA)
01
Overview
Phase 2, randomised, double-blind trial in spinocerebellar ataxia (SCA) comparing CAD-1883 with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events at 12 weeks. Planned start Jun 2021; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedDouble-blind
CAD-1883
CAD-1883 150 mg BID
Placebo
Matching Placebo BID
03
Who it enrols
Adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA1, 2, 3, 6, 7, 8, 10, 17, or ARCA1) with a SARA score between 8 and 30 and ability to ambulate 8 meters.
04
Endpoints
Primary
Incidence of Adverse Events
Secondary
Scale for the Assessment and Rating of Ataxia
Clinician/Patient Rating of Ataxia and Symptoms
Patient Quality of Life Measures
Wearable Sensor Measurements
Beyond the preview
Go deeper on NCT04301284.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301284.